公开(公告)号：EP3221363A2

公开(公告)日：2017-09-27

申请号：EP15816276.8

申请日：2015-11-19

申请人： Bristol-Myers Squibb Company

发明人： LONBERG, Nils ,  KORMAN, Alan J. ,  BARNHART, Bryan C. ,  YAMNIUK, Aaron P. ,  SRINIVASAN, Mohan ,  HENNING, Karla A. ,  LEI, Ming ,  SEGA, Emanuela ,  GOODENOUGH, Angela ,  JURE-KUNKEL, Maria N. ,  CHEN, Guodong ,  SACK, John ,  HUANG, Richard ,  CORBETT, Martin J. ,  MYERS, Joseph E. ,  SCHWEIZER, Liang ,  HATCHER, Sandra V. ,  HUANG, Haichun ,  ZHANG, Pingping

IPC分类号： C07K16/28 ,  C07K16/40 ,  C07K16/30 ,  A61K39/395 ,  A61P35/00

摘要： The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

摘要翻译： 本发明提供以高亲和力结合人分化簇73（CD73）并且抑制CD73的活性并且任选地介导抗体依赖性CD73内化的分离的单克隆抗体，特别是人抗体。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和表达本发明抗体的方法。 还提供了包含本发明抗体的免疫缀合物，双特异性分子和药物组合物。 本发明还提供了使用本发明的抗体抑制表达CD73的肿瘤细胞生长的方法，包括治疗各种癌症的方法。

公开(公告)号：EP3221363B1

公开(公告)日：2020-05-06

申请号：EP15816276.8

申请日：2015-11-19

申请人： Bristol-Myers Squibb Company

发明人： LONBERG, Nils ,  KORMAN, Alan J. ,  BARNHART, Bryan C. ,  YAMNIUK, Aaron P. ,  SRINIVASAN, Mohan ,  HENNING, Karla A. ,  LEI, Ming ,  SEGA, Emanuela ,  GOODENOUGH, Angela ,  JURE-KUNKEL, Maria N. ,  CHEN, Guodong ,  SACK, John ,  HUANG, Richard ,  CORBETT, Martin J. ,  MYERS, Joseph E. ,  SCHWEIZER, Liang ,  HATCHER, Sandra V. ,  HUANG, Haichun ,  ZHANG, Pingping

IPC分类号： C07K16/28 ,  C07K16/40 ,  C07K16/30 ,  A61K39/395 ,  A61P35/00

公开(公告)号：EP3725808A1

公开(公告)日：2020-10-21

申请号：EP20164125.5

申请日：2015-11-19

申请人： Bristol-Myers Squibb Company

发明人： LONBERG, Nils ,  KORMAN, Alan J. ,  BARNHART, Bryan C. ,  YAMNIUK, Aaron P. ,  SRINIVASAN, Mohan ,  HENNING, Karla A. ,  LEI, Ming ,  SEGA, Emanuela ,  GOODENOUGH, Angela ,  JURE-KUNKEL, Maria N. ,  CHEN, Guodong ,  SACK, John ,  HUANG, Richard ,  CORBETT, Martin J. ,  MYERS, Joseph E. ,  SCHWEIZER, Liang ,  HATCHER, Sandra V. ,  HUANG, Haichun ,  ZHANG, Pingping

IPC分类号： C07K16/28 ,  C07K16/40 ,  C07K16/30 ,  A61K39/395 ,  A61P35/00

摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.